Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report

BACKGROUND: To manage severe or potentially severe cases of CoronaVirus Disease 2019 (COVID-19), therapeutic monoclonal antibodies targeting Spike protein of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have been designed. It has been noted in vitro that upon exposure to these treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenaux, Honorine, Gueneau, Romain, Chaghouri, Amal, Henry, Benoît, Mouna, Lina, Roque-Afonso, Anne-Marie, Vauloup-Fellous, Christelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649676/
https://www.ncbi.nlm.nih.gov/pubmed/34876033
http://dx.doi.org/10.1186/s12879-021-06902-1
_version_ 1784611051240685568
author Fenaux, Honorine
Gueneau, Romain
Chaghouri, Amal
Henry, Benoît
Mouna, Lina
Roque-Afonso, Anne-Marie
Vauloup-Fellous, Christelle
author_facet Fenaux, Honorine
Gueneau, Romain
Chaghouri, Amal
Henry, Benoît
Mouna, Lina
Roque-Afonso, Anne-Marie
Vauloup-Fellous, Christelle
author_sort Fenaux, Honorine
collection PubMed
description BACKGROUND: To manage severe or potentially severe cases of CoronaVirus Disease 2019 (COVID-19), therapeutic monoclonal antibodies targeting Spike protein of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have been designed. It has been noted in vitro that upon exposure to these treatments, mutations could be selected. CASE PRESENTATION: We here report the case of an immunosuppressed patient infected with a B.1.1.7 variant, who received a combination of monoclonal antibodies, and subsequently selected mutations K417N, E484K and Q493R on Spike protein of SARS-CoV-2. CONCLUSIONS: Our case raises the importance of monitoring SARS-CoV-2 mutations in patients receiving monoclonal antibodies and having persistent excretion of the virus, in order to offer optimal management of their infection, and strengthen prevention measures to avoid subsequent transmission of these selected variants.
format Online
Article
Text
id pubmed-8649676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86496762021-12-07 Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report Fenaux, Honorine Gueneau, Romain Chaghouri, Amal Henry, Benoît Mouna, Lina Roque-Afonso, Anne-Marie Vauloup-Fellous, Christelle BMC Infect Dis Case Report BACKGROUND: To manage severe or potentially severe cases of CoronaVirus Disease 2019 (COVID-19), therapeutic monoclonal antibodies targeting Spike protein of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have been designed. It has been noted in vitro that upon exposure to these treatments, mutations could be selected. CASE PRESENTATION: We here report the case of an immunosuppressed patient infected with a B.1.1.7 variant, who received a combination of monoclonal antibodies, and subsequently selected mutations K417N, E484K and Q493R on Spike protein of SARS-CoV-2. CONCLUSIONS: Our case raises the importance of monitoring SARS-CoV-2 mutations in patients receiving monoclonal antibodies and having persistent excretion of the virus, in order to offer optimal management of their infection, and strengthen prevention measures to avoid subsequent transmission of these selected variants. BioMed Central 2021-12-07 /pmc/articles/PMC8649676/ /pubmed/34876033 http://dx.doi.org/10.1186/s12879-021-06902-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Fenaux, Honorine
Gueneau, Romain
Chaghouri, Amal
Henry, Benoît
Mouna, Lina
Roque-Afonso, Anne-Marie
Vauloup-Fellous, Christelle
Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
title Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
title_full Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
title_fullStr Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
title_full_unstemmed Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
title_short Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
title_sort emergence of sars-cov-2 resistance mutations in a patient who received anti-sars-cov2 spike protein monoclonal antibodies: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649676/
https://www.ncbi.nlm.nih.gov/pubmed/34876033
http://dx.doi.org/10.1186/s12879-021-06902-1
work_keys_str_mv AT fenauxhonorine emergenceofsarscov2resistancemutationsinapatientwhoreceivedantisarscov2spikeproteinmonoclonalantibodiesacasereport
AT gueneauromain emergenceofsarscov2resistancemutationsinapatientwhoreceivedantisarscov2spikeproteinmonoclonalantibodiesacasereport
AT chaghouriamal emergenceofsarscov2resistancemutationsinapatientwhoreceivedantisarscov2spikeproteinmonoclonalantibodiesacasereport
AT henrybenoit emergenceofsarscov2resistancemutationsinapatientwhoreceivedantisarscov2spikeproteinmonoclonalantibodiesacasereport
AT mounalina emergenceofsarscov2resistancemutationsinapatientwhoreceivedantisarscov2spikeproteinmonoclonalantibodiesacasereport
AT roqueafonsoannemarie emergenceofsarscov2resistancemutationsinapatientwhoreceivedantisarscov2spikeproteinmonoclonalantibodiesacasereport
AT vauloupfellouschristelle emergenceofsarscov2resistancemutationsinapatientwhoreceivedantisarscov2spikeproteinmonoclonalantibodiesacasereport

Ejemplares similares